1. Home
  2. RITM vs GKOS Comparison

RITM vs GKOS Comparison

Compare RITM & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RITM
  • GKOS
  • Stock Information
  • Founded
  • RITM 2011
  • GKOS 1998
  • Country
  • RITM United States
  • GKOS United States
  • Employees
  • RITM N/A
  • GKOS N/A
  • Industry
  • RITM Real Estate Investment Trusts
  • GKOS Medical/Dental Instruments
  • Sector
  • RITM Real Estate
  • GKOS Health Care
  • Exchange
  • RITM Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • RITM 6.1B
  • GKOS 5.4B
  • IPO Year
  • RITM N/A
  • GKOS 2015
  • Fundamental
  • Price
  • RITM $11.10
  • GKOS $91.04
  • Analyst Decision
  • RITM Strong Buy
  • GKOS Strong Buy
  • Analyst Count
  • RITM 8
  • GKOS 13
  • Target Price
  • RITM $14.25
  • GKOS $122.08
  • AVG Volume (30 Days)
  • RITM 6.6M
  • GKOS 1.8M
  • Earning Date
  • RITM 10-30-2025
  • GKOS 10-29-2025
  • Dividend Yield
  • RITM 8.99%
  • GKOS N/A
  • EPS Growth
  • RITM 46.96
  • GKOS N/A
  • EPS
  • RITM 1.45
  • GKOS N/A
  • Revenue
  • RITM $3,961,432,000.00
  • GKOS $469,820,000.00
  • Revenue This Year
  • RITM N/A
  • GKOS $30.89
  • Revenue Next Year
  • RITM $4.75
  • GKOS $24.36
  • P/E Ratio
  • RITM $7.67
  • GKOS N/A
  • Revenue Growth
  • RITM 32.03
  • GKOS 30.38
  • 52 Week Low
  • RITM $9.13
  • GKOS $73.16
  • 52 Week High
  • RITM $12.74
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • RITM 50.28
  • GKOS 59.97
  • Support Level
  • RITM $10.82
  • GKOS $88.60
  • Resistance Level
  • RITM $11.31
  • GKOS $97.22
  • Average True Range (ATR)
  • RITM 0.19
  • GKOS 5.08
  • MACD
  • RITM 0.05
  • GKOS 1.22
  • Stochastic Oscillator
  • RITM 65.72
  • GKOS 59.75

About RITM Rithm Capital Corp.

Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: